Format

Send to

Choose Destination
J Cachexia Sarcopenia Muscle. 2016 Mar;7(1):60-7. doi: 10.1002/jcsm.12068. Epub 2015 Oct 27.

Evaluation of C-terminal Agrin Fragment as a marker of muscle wasting in patients after acute stroke during early rehabilitation.

Author information

1
Center for Stroke Research CSB Charite Universitätsmedizin Berlin Germany; German Centre for Cardiovascular Research (DZHK), partner site Berlin Germany.
2
Center for Stroke Research CSB Charite Universitätsmedizin Berlin Germany.
3
Innovative Clinical Trials, Department of Cardiology and Pneumology University Medicine Göttingen Germany.
4
Innovative Clinical Trials, Department of Cardiology and Pneumology University Medicine Göttingen Germany; 1st Department of Internal Medicine Comenius University Bratislava Slovak Republic.
5
Neurotune AG Wagistrasse 27a Schlieren Switzerland.
6
Department of Intensive Care Medicine Inselspital, University Hospital of Bern Switzerland.
7
Department of Neurology Brandenburgklinik Bernau Germany.
8
Center for Stroke Research CSB Charite Universitätsmedizin Berlin Germany; German Centre for Cardiovascular Research (DZHK), partner site Berlin Germany; Department of Cardiology Charite Universitätsmedizin Berlin Germany.

Abstract

BACKGROUND:

C-terminal Agrin Fragment (CAF) has been proposed as a novel biomarker for sarcopenia originating from the degeneration of the neuromuscular junctions. In patients with stroke muscle wasting is a common observation that predicts functional outcome. We aimed to evaluate agrin sub-fragment CAF22 as a marker of decreased muscle mass and physical performance in the early phase after acute stroke.

METHODS:

Patients with acute ischaemic or haemorrhagic stroke (n = 123, mean age 70 ± 11 y, body mass index BMI 27.0 ± 4.9 kg/m(2)) admitted to inpatient rehabilitation were studied in comparison to 26 healthy controls of similar age and BMI. Functional assessments were performed at begin (23 ± 17 days post stroke) and at the end of the structured rehabilitation programme (49 ± 18 days post stroke) that included physical assessment, maximum hand grip strength, Rivermead motor assessment, and Barthel index. Body composition was assessed by bioelectrical impedance analysis (BIA). Serum levels of CAF22 were measured by ELISA.

RESULTS:

CAF22 levels were elevated in stroke patients at admission (134.3 ± 52.3 pM) and showed incomplete recovery until discharge (118.2 ± 42.7 pM) compared to healthy controls (95.7 ± 31.8 pM, p < 0.001). Simple regression analyses revealed an association between CAF22 levels and parameters of physical performance, hand grip strength, and phase angle, a BIA derived measure of the muscle cellular integrity. Improvement of the handgrip strength of the paretic arm during rehabilitation was independently related to the recovery of CAF22 serum levels only in those patients who showed increased lean mass during the rehabilitation.

CONCLUSIONS:

CAF22 serum profiles showed a dynamic elevation and recovery in the subacute phase after acute stroke. Further studies are needed to explore the potential of CAF22 as a serum marker to monitor the muscle status in patients after stroke.

KEYWORDS:

C‐terminal Agrin Fragment; Muscle wasting; Physical performance; Post‐stroke rehabilitation; Skeletal muscle mass; Stroke

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center